A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

Grants and Contracts Details

Effective start/end date10/28/158/7/18


  • Vertex Pharmaceuticals Inc: $30,417.00